44 results about "T cell differentiation" patented technology

The invention provides a method for preparing an anti-tumor T cell in vitro through DC (dendritic cell, namely antigen presenting cell), wherein the anti-tumor T cell is a tumor total RNA-loaded DC amplification and enrichment anti-tumor T cell. The invention also provides a preparation method of the anti-tumor T cell and an anti-tumor drug or inoculation vaccine taking the anti-tumor T cell as an active ingredient. According to the invention, a specific anti-tumor T cell is amplified in vitro by taking the tumor total RNA-loaded DC as a platform, a small amount of tumor total RNA is amplified to an enough amount in vitro so as to realize clinical application, and the in-vivo anti-tumor effect in an IC (intracranial) tumor-bearing model is evaluated, including how the mature state of DC and the cell factor combination adjust the differentiation of the anti-tumor T cell as well as the synergistic anti-tumor effect thereof in a preclinical experiment model.

The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead / winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighbouring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.

The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.

A method for generating a population of functional regulatory T cells (TREG-cells), which are a subset of the T cell lineage having the ability to actively suppress immune activation and maintain peripheral immune tolerance, is described. The method comprises the steps of first culturing haemopoietic stem cells (HSC) and / or haemopoietic progenitor cells in the presence of a Notch ligand that supports T cell differentiation, and then isolating T cells having a TREG-cell surface marker phenotype. A suitable source of HSC is cord blood (CB) and a suitable culture medium is OP9 cells engineered to express the Notch Ligand Delta-Like 1 (DL1) (OP9-DL1 cell line). Examples of TREG-cell surface marker phenotypes are CD4+CD25+, CD45RO+, CD45RA+, CD127LOW−, LAG-3 and / or CD39+.

Methods are disclosed to identify T lymphocyte genes that are differentially expressed upon exposure to a pathogen (viral or bacterial), immunogen, antigen, or in a sterile inflammatory disease, autoimmune disease, immunodeficiency disease, lymphocytic cancers, or graft versus host rejection. The method involves the preparation of a gene expression profile of a T lymphocyte population exposed to a pathogen or isolated from a subject having one of the aforementioned pathologies and comparing that profile to a profile prepared from quiescent T lymphocytes. The present invention is useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signalling molecules. Related methods for identifying therapeutic or prophylatic immunomodulatory agents are present. Articles of manufacture are disclosed that comprise selected grouping of nucleic acids, affixed to a solid support, that correspond to genes that are differentially expressed in various populations or subpopulations of T lymphocytes at variations stages of T cell differentiation, in quiescent versus activated T lymphocytes or normal versus diseased T lymphocytes.

The invention discloses application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation, relieving inflammation and alleviating bone injury. The BA and its derivatives involved in the invention can inhibit T cell differentiation, has an anti-inflammatory effect in autoimmune diseases so as to relieve inflammation, and can be used for preparation of drugs treating autoimmune diseases like rheumatoid arthritis and experimental encephalomyelitis, etc.

The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells.The inhibitor that inhibits differentiation of T cells into Th1 cells contains, as an active ingredient, pitavastatin or a salt thereof.

A method of treating a T-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces T-cell differentiation or t-cell inflammatory cytokine generation.

The present invention discloses applications of interleukin-21 in preparation of a stem cell-like memory T cell in vitro amplification inducer. According to the present invention, with the addition of interleukin-21 as an inducer to a T cell induction culture medium, the differentiation amplification of Naive CD8+ T cells can be induced to obtain TSCM cells, the forming proportion and the absolute number of the TSCM cells are significantly increased, and the effect is significantly superior to the effect of the inducer IL-2 universally used in the cell adoptive immunotherapy; and the interleukin-21 is the natural cytokine secreted by human body, has the high safety, does not have the drug toxicity and other problems, can provide the good technical support for the extensive development of the adoptive immunotherapy, and has the important promotion significance.

The culture method to differentiate embryonic stem cell into T cell comprises: preparing embryo body; transferring the body into differentiated culture medium; digesting the body into single cell by pancreatin; labeling the opposite antibody of T cell special surface cell; detecting T cell quantity with a FCM; and obtaining the need T cell. It also provides the opposite culture medium. This invention overcomes the defect in prior art, induces T lymphocyte from embryonic stem cell directly, and provides a simple and effective external model for research and a safe source for clinical application of T cell.

The inventoin provides a use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases.

The invention belongs to the field of biomedicine, and relates to a non-small-cell lung carcinoma molecular marker and applications thereof. According to the present invention, the deep research results show that T cell differentiation protein 2 (MAL2) gene is closely related to the occurrence of non-small-cell lung carcinoma, such that the T cell differentiation protein 2 (MAL2) gene can be usedas the molecular marker for early diagnosis of non-small-cell lung carcinoma; by determining the functions of the key pathogenic gene in non-small-cell lung carcinoma, the molecular target in non-small-cell lung carcinoma can be determined so as to accelerate the progress of the individualized targeted therapy of non-small-cell lung carcinoma; specifically the present invention discloses applications of the MAL2 gene and protein in gene molecular markers for the detection of non-small-cell lung carcinoma, and provides applications of the MAL2 gene and protein in preparation of clinical diagnostic reagents or kits for tumors; and the new gene and the protein highly expressed in non-small-cell lung carcinoma are found so as to provide the new approach for the diagnosis and treatment of tumors.

The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and / or for inducing differentiation into regulator T cells from undifferentiated T cells and / or promoting proliferation of regulator T cells.

The invention discloses new application of protocatechuic acid in the aspect of immune function promotion of livestock, especially in the aspects of peripheral blood CD4+ / CD8+T cell dynamic balance maintenance of livestock, cytokine secreting adjustment and the like. Influences of protocatechuic acid on the immune function, especially on T cell differentiation, of livestock are evaluated, 20 mg of protocatechuic acid is applied to each kilogram of body weight, protocatechuic acid is continuously taken orally for seven days, and results show that protocatechuic acid can effectively increase the peripheral blood CD4+ / CD8+T ratio, promote cytokine secreting in thymuses and the spleen and selectively adjust related genes of the immune system. The invention further provides a livestock immune promoter containing an effective dose of protocatechuic acid. Medical auxiliary materials can be added and prepared into various preparations, such as powder, tablets, granules and oral liquid, according to a conventional preparation method in the field. The effective dose is 5-40 mg for each kilogram of body weight, and the preparation is taken in a mixing mode or with water.

The invention relates to a lymphocyte culture method, and in particular discloses a culturing method of adenovirus gene-modifying tumor specificity cytotoxic T lymphocyte. The method comprises: taking 150-200ml of bleeding of the umbilicus or autologous peripheral blood for single karyocyte separation, separately culturing DC cells by adhering to a wall for 2h, and performing T lymphocyte preculture on the non-adhered cells in an IL-2-contained culture medium; collecting mature DC after the DC cells are mature through induction of iAPA factor adenovirus infection, stimulating the autologous primary T lymphocyte to differentiate into cytotoxic T lymphocyte according to an effect target ratio of DC to T being 1 to 10, and observing and recording multiplication capacity of CTL and detecting the cytotoxicity of the CTL. The limitation of a blood component single sampling machine is solved, collected blood volume is less, burden of a patient is reduced, and iAPA-DC can be observed in vitro to stimulate and differentiate the primary T lymphocyte into tumor specificity cytotoxic T lymphocyte.

To provide a medicinal composition for preventing or treating a Th1 type immunological disease. A medicinal composition to be used in preventing or treating a Th1 type immunological disease containing as the active ingredient a substance capable of differentiating T cells into Th2 type cells by acting on GC-A, which is an NP receptor expressed in dendritic cells, to thereby promote cGMP production and control the cytokine production in the dendritic cells is obtained.

Disclosed herein are compositions and methods for enhancing T-cell activity by modulating a miRNA so as to improve T-cell therapies, infectious disease therapies and down-regulate auto-immune responses.

The present invention relates to a composition and a method for inducing CD4+ T cells to differentiate into regulatory T cells and proliferate through an induced T cell co-stimulator ligand (ICOSL) or an ICOSL-overexpressing mesenchymal stem cell and for preventing or treating regulatory T cell-mediated diseases. The induced T cell co-stimulator ligand (ICOSL) or ICOSL-overexpressing mesenchymal stem cell according to the present invention effectively suppresses the proliferation of PBMCs, induces the expression of an ICOS in regulatory T cells, thereby inducing the differentiation and proliferation of the regulatory T cells through a PI3K-Akt mechanism, and thus can effectively prevent, treat, or enhance regulatory T cell-mediated diseases.

The invention relates to an in-vitro culture kit, in particular to an in-vitro culture kit for CMV-CTLs (human cytomegalovirus-cytotoxic T lymphocytes). The in-vitro culture kit comprises a CMV antigenic peptide coating bottle for inducing CTL cells to be differentiated, a coating bottle for inducing T cells to be differentiated, cell factors stimulating CTL and T cells to be split and proliferated as well as cell factors enabling associated antigens carried by the T cells to stimulate the CMV-CTLs to proliferate and mature. Complicated reagents and consumables required for in-vitro culture of the CMV-CTLs are standardly combined, all operation is standard and modeled, the working efficiency is improved, and the cell quality and yield differences brought by worker operation are reduced.

The invention discloses selenium-doped prussian blue nano-enzyme for regulating intestinal cells to treat colitis, a preparation method and application thereof, wherein a layer of selenium is doped on the surface of hollow mesoporous prussian blue by a hard template method. The selenium-doped prussian blue nano-enzyme disclosed by the invention has a good capability of removing active oxygen and a function of inhibiting intestinal epithelial cell lipid peroxidation and T cell differentiation, and can be used for relieving the occurrence of intestinal inflammatory diseases.

The invention belongs to the technical field of allergen identification, and provides a method for identifying allergens. A sample to be identified is used for stimulating immature dendritic cells, flow cytometry is adopted for detecting expression of cell surface markers (MHC II and CD86), and an ELISA method is adopted for detecting the generation condition of cell factors (IL-6, IFN-gamma and TNF-alpha). Meanwhile, whether the sample to be identified is the allergen or not is judged according to the effect of the allergen to be identified on T cell differentiation after the dendritic cells are stimulated in vitro. The method disclosed by the invention is simple and effective, and provides a reference basis for rapidly identifying allergens.

The invention relates to an application of peritoneal cells to induction of differentiation of T cells into regulatory T cells, belongs to the field of medicines, aims to solve the problems that obtaining enough regulatory T cells from tissue for treatment is difficult, and few obtaining methods exist, and provides an application of peritoneal cells to induction of differentiation of T cells intoregulatory T cells. The method comprises the following steps of firstly, detecting the expression situation of various markers on surfaces of the peritoneal cells, confirming whether the peritoneal cells are a mixture of various suppressor cells of B cells, macrophages, the T cells and the like, and confirming that the peritoneal cells have immunosuppressive action; and then performing co-cultureon the peritoneal cells and the T cells, wherein the results confirm that CD3+CD4+CD25+Foxp3+ regulatory T cells are obviously increased, and the peritoneal cells can induce the differentiation of T cells into regulatory T cells, and can promote generation of the regulatory T cells. The invention provides a new method for preparing the regulatory T cells.

The present invention relates to methods of increasing proliferation and / or programming differentiation status of T cells comprising genetically modifying the cells to inducibly express FOXO1-3A or TCF7 when activated. Also provided are engineered cells modified to inducibly express FOXO1-3A or TCF7 when activated; and methods of treating disease using the engineered cells. Also provided are methods of screening and identifying receptors that specifically bind an antigen or antigens that specifically bind a receptor.

Provided is an isolated or purified T cell comprising an antigen-specific receptor, wherein the antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein the T cell has been modified to express a transcription factor at a level that is higher than the level of the transcription factor expressed by a T cell that has not been modified to express the transcription factor, wherein the transcription factor is V-Myb Avian Myeloblastosis Viral Oncogene Homolog (c-Myb), a functional variant of c-Myb, or a functional fragment of c-Myb. Related populations of cells, pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells are also provided.

The culture method to differentiate embryonic stem cell into T cell comprises: preparing embryo body; transferring the body into differentiated culture medium; digesting the body into single cell by pancreatin; labeling the opposite antibody of T cell special surface cell; detecting T cell quantity with a FCM; and obtaining the need T cell. It also provides the opposite culture medium. This invention overcomes the defect in prior art, induces T lymphocyte from embryonic stem cell directly, and provides a simple and effective external model for research and a safe source for clinical application of T cell.

The invention relates to the field of biomedicine, and discloses a biomarker for regulating CD4 + T cells differentiation and proliferation of type 1 diabetes mellitus, which comprises circRNA000324; the invention also discloses an application thereof. According to the invention, a new target is provided for the mechanism research of T1DM autoimmunity, a new evidence is provided for the action mechanism of non-encoding RNA (ncRNA) and related ceRNAs networks in T1DM pathogenesis, and more possibilities are provided for predicting or preventing and treating type 1 diabetes mellitus.

A method is described herein for generating antigen-specific memory T. cells for effective immunotherapy responses using pan inhibitors of lysine deacetylase (KDAC), The present invention features the introduction of pan KDAC inhibitors during T-cell culture and / or vaccination to tune T cell differentiation into memory T cells for persistent antigen-specific responses. The current invention can be applied to the generation of personalized immunotherapies, including: 1) durable immunotherapy generation for the pharmaceutical industry; 2) patient-specific immunotherapy tor personalized medicine; and 3) specific memory T cell population generation or T cell therapy for cancer and / or infections for personalized cancer immunotherapy. The present invention relates to a method to induce acquired T cell differentiation towards the generation of specific memory T cells with selective functions for treatment.

The invention relates to the field of medical immunology, and discloses application of a compound shown as a formula (I) in preparing a medicament used for inducing T cells to be differentiated into FoxP3+CD4+ regulatory T cells and inhibiting the T cells from proliferating, wherein the compound shown as the formula (I) belongs to 4-(cyclohexyl)-aminoquinazoline compounds. The compound shown as the formula (I) plays a remarkable role in inhibiting the T cells from proliferating and inducing the T cells to be differentiated into the FoxP3+CD4+ regulatory T cells, and the medicament which is prepared by the compound and is used for inducing the T cells to be differentiated into the FoxP3+CD4+ regulatory T cells and inhibiting the T cells from proliferating can be used for autoimmune diseases and transplantation rejection.

The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and / or for inducing differentiation into regulator T cells from undifferentiated T cells and / or promoting proliferation of regulator T cells.